Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Sunnybrook Health Sciences Centre
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05561205CT.gov rTMS for Apathy Clinical Trial | — | Recruiting | — | — | — |
NCT01825577CT.gov Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia. | — | Terminated | — | — | — |
NCT00914095CT.gov Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II) | — | Completed | — | — | — |
NCT00792662CT.gov Improving Function, Quality of Life, Glycemia in Diabetics With Dementia | — | Withdrawn | — | — | — |
NCT00495820CT.gov Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study | — | Completed | — | — | — |
NCT00254033CT.gov Apathy Associated With Alzheimer's Disease | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Dementia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Methylphenidate (this asset) | Sunnybrook Health Sciences Centre | Approved | BB · 66 |
| Risperidone | Hannover Medical School | P4 | BBB |
| Citalopram | Hannover Medical School | P4 | BBB |
| Galantamine Hydrobromide | Janssen Pharmaceutica N.V., Belgium | P3 | BB |
| Escitalopram | Ohio State University | P4 | BB |
| Memantine | Zealand University Hospital | P4 | BB |
| Ioflupane | Mayo Clinic | P4 | BB |
| Olanzapine | Hannover Medical School | P4 | BB |
| Sertraline | Hannover Medical School | P4 | BB |
+42 more in the Dementia cohort
Other indications for Methylphenidate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Attention Deficit-Hyperactivity Disorder | — | P4 | BBB · 76 |
| Multiple Sclerosis | — | P3 | BB · 70 |
| Alzheimer Disease | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Methylphenidate in Dementia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/methylphenidate-dementia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →